AI-generated summary
The authors evaluated a 1550 nm erbium:glass fractional laser for facial acne vulgaris in 45 patients treated four times at four-week intervals, with no control group. They report lesion counts and IGA scores fell after treatment, with a mean lesion reduction of 72% at half a year, 79% at one year and 75% at two years in patients followed up. Side effects were mostly transient redness and swelling.
- Participants
- 45
- Who or what was studied
- 45 patients (9 male, 36 female) with facial acne vulgaris
- Wavelengths
- 1550 nm
- Limits stated in the abstract
- The study had no control group, a small sample, and 8 patients were lost to follow-up, with fewer patients in the longer follow-up windows.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 1550 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Control group, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.